We are live on
!
Find out more
CC
Caxton Corporation Portfolio holdings
AUM
$4.02M
1-Year Est. Return
256.08%
This Fund
S&P 500
This Quarter
Est. Return
-9.68%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$80.4M
AUM Growth
-$41.9M
(-34%)
Cap. Flow
-$30.5M
Cap. Flow
% of AUM
-37.98%
Top 10 Holdings %
Top 10 Hldgs %
79.62%
Holding
53
New
1
Increased
2
Reduced
24
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.99M |
| 2 |
ACLX
Arcellx
ACLX
|
+$1.49M |
| 3 |
ELEV
Elevation Oncology
ELEV
|
+$52K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardiff Oncology
CRDF
|
+$15.2M |
| 2 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$5.72M |
| 3 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$5.55M |
| 4 |
LUXA
Lux Health Tech Acquisition Corp. Class A Common Stock
LUXA
|
+$1.96M |
| 5 |
iShares MSCI EAFE ETF
EFA
|
+$1.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.31% |
| 2 | Financials | 10.5% |
| 3 | Communication Services | 5.09% |
| 4 | Technology | 4.29% |
| 5 | Consumer Discretionary | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xeris Biopharma Holdings
XERS
$1.52B
| $15.5M | 19.22% |
6,039,028
-271,518
| -4% | -$663K |
|
2
Savara
SVRA
$1.13B
| $9.03M | 11.23% |
6,896,551
-20,000
| -0.3% | -$24.1K |
|
3
SPDR Gold Trust
GLD
$130B
| $7.37M | 9.17% |
40,820
| – | – |
|
|
4
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $7.2M | 8.95% |
15,947
+8,967
| +128% | +$3.99M |
|
|
MTEM
5
DELISTED
Molecular Templates, Inc.
MTEM
| $7.08M | 8.81% |
136,866
-5,667
| -4% | -$250K |
|
6
SCYNEXIS
SCYX
$42.4M
| $6.74M | 8.38% |
215,493
-3,105
| -1% | -$119K |
|
|
PSTH
7
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
| $4.51M | 5.61% |
227,000
| – | – |
|
8
Rezolute
RZLT
$444M
| $4.03M | 5.02% |
1,193,473
| – | – |
|
|
ADXN
9
Addex Therapeutics
ADXN
$7.22M
| $1.35M | 1.68% |
13,297
| – | – |
|
|
ACLX
10
DELISTED
Arcellx
ACLX
| $1.25M | 1.55% |
+88,820
| New | +$1.49M |
|
11
Alphabet (Google) Class C
GOOG
$4.22T
| $1.1M | 1.37% |
7,900
-80
| -1% | -$10.9K |
|
12
Microsoft
MSFT
$2.93T
| $1.01M | 1.25% |
3,263
-36
| -1% | -$10.8K |
|
|
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $970K | 1.21% |
3,896
| – | – |
|
14
Intuit
INTU
$79.6B
| $945K | 1.18% |
1,965
-24
| -1% | -$12.3K |
|
15
S&P Global
SPGI
$133B
| $912K | 1.13% |
2,225
-26
| -1% | -$10.6K |
|
16
TransDigm Group
TDG
$67.9B
| $906K | 1.13% |
1,391
-16
| -1% | -$10.3K |
|
17
Visa
V
$682B
| $872K | 1.08% |
3,931
-50
| -1% | -$10.8K |
|
18
Mastercard
MA
$480B
| $871K | 1.08% |
2,438
-31
| -1% | -$11.1K |
|
19
Moody's
MCO
$89.2B
| $866K | 1.08% |
2,567
-33
| -1% | -$11.1K |
|
20
Mondelez International
MDLZ
$78.3B
| $842K | 1.05% |
13,405
-177
| -1% | -$11.5K |
|
21
American Tower
AMT
$79.2B
| $803K | 1% |
3,196
-44
| -1% | -$10.7K |
|
22
Fair Isaac
FICO
$29.2B
| $800K | 0.99% |
1,715
-24
| -1% | -$11.3K |
|
23
Salesforce
CRM
$140B
| $699K | 0.87% |
3,294
-52
| -2% | -$11.2K |
|
24
Walt Disney
DIS
$170B
| $686K | 0.85% |
5,002
-80
| -2% | -$11.6K |
|
25
Whirlpool
WHR
$2.48B
| $664K | 0.83% |
3,843
-63
| -2% | -$12.8K |
|
Similar funds
PCM
EAMS
RCP
RA
CGA
HFA
ABA
UOMF
Caxton Corporation's Q1 2022 Portfolio in Review
As of Q1 2022, Caxton Corporation held 53 positions worth $80.4M, down 34% from $122M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Caxton Corporation withdrew a net $30.5M in Q1 2022, closing 16 positions and reducing 24 holdings. Its most notable exit was Cardiff Oncology, an estimated $15.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 66% a quarter earlier, followed by Financials and Communication Services.
Against the trend, Caxton Corporation opened a new position in Arcellx worth $1.25M.
- Caxton Corporation's largest Q1 2022 buy was Arcellx: 88,820 shares worth $1.25M.
- Caxton Corporation added most to State Street SPDR S&P 500 ETF Trust in Q1 2022, an estimated $3.99M increase.
- Caxton Corporation's biggest Q1 2022 reduction was Xeris Biopharma Holdings, cutting an estimated $663K.
- Caxton Corporation fully exited Cardiff Oncology in Q1 2022, selling an estimated $15.2M.
- Caxton Corporation's ten largest holdings make up 80% of its $80.4M portfolio in Q1 2022.
- Caxton Corporation opened 1 new position and closed 16 in Q1 2022.
- Caxton Corporation's portfolio value fell 34% quarter-over-quarter to $80.4M.
Based on Caxton Corporation's 13F filing for Q1 2022, filed 16 May 2022.